Overseed
Medical cannabis: from seed to purified pharmaceutical grade active ingredients
Medical cannabis: from seed to purified pharmaceutical grade active ingredients
Overseed is the first French biotech company licensed by ANSM to conduct R&D on cannabis production for pharmaceutical purposes. Combining expertise in genetics, agronomy, organic chemistry, and pharma, the company aims to become a leading expert in therapeutic cannabis production. Overseed will produce GACP and GMP certified dried flowers, full spectrum extracts, and purified pharmaceutical grade active ingredients for laboratories. The company's research and experimentation focus on meeting patient and health industry expectations by ensuring production sovereignty, proximity of collaborations, and certified quality of cultivated products, in direct connection with medical and scientific studies. Founded in 2021 and headquartered in France, Overseed secured a €6.70M Series A investment on 03 July 2024 from UI Investissement and Blast.club. This investment showcases confidence in Overseed's patient-driven culture, emphasizing people, product quality, and value creation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €6.70M | 2 |
|
03 Jul 2024 |
| Seed | Unknown | - | 30 Nov 2021 |
No recent news or press coverage available for Overseed.
We care about your data, and we'd love to use cookies make your experience better.
